radiolabeled RPS-088 (Ratio Therapeutics/Weill Cornell Medicine/Cornell University)

N/A

Report date: 2025/06/11 11:25:22
NME

Base Information

Drug Nameradiolabeled RPS-088 (Ratio Therapeutics/Weill Cornell Medicine/Cornell University)
Drug Alias NamePSMA-targeting radioligand therapy (Ratio Therapeutics/Weill Cornell Medicine/Cornell University)[134Ce]Ce-RPS-088225Ac-RPS-088Cerium-134- RPS-088RPS-088-[225Ac] +[8] 
ClassificationSmall moleculesRadiation-emitting products > Radioactive diagnostic agentDiagnostic agent (In vivo) +[4] 
Mechanisms of ActionProstate-Specific Membrane Antigen modulatorsPositron-emission tomography enhancers
TargetsProstate-Specific Membrane Antigen
Therapy Area/IndicationsProstatic Neoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesCornell University
China Registration ClassN/A

Develop Information

Active CompaniesRatio Therapeutics IncWeill Cornell MedicineCornell University
Inactive CompaniesN/A
Active IndicationsProstatic Neoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A